5/12/2021 – RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury May 12, 2021j3ff1 Read More
4/22/2021 – RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs April 22, 2021j3ff1 Read More
2/8/2021 – Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI February 8, 2021j3ff1 Read More
2/8/2021 – RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split February 8, 2021j3ff1 Read More
1/8/2021 – RespireRx Pharmaceuticals Inc. to Participate in Upcoming January Virtual Investor Conferences January 8, 2021j3ff1 Read More
1/5/2021 – RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split January 5, 2021j3ff1 Read More
10/27/2020 – RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows October 27, 2020j3ff1 Read More
10/06/2020 – RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury October 6, 2020j3ff1 Read More
